




























The oncosuppressor TP53, which is mutated or 
inactivated in more than 50% of all human neoplasms, 
is widely known for its ability to orchestrate a 
transcriptional stress response that can have multiple 
outcomes including senescence and cell death [1]. Thus, 
in reaction to a wide array of adverse conditions (e.g., 
DNA damage, oncogene deregulation), the TP53 
protein gets stabilized by post-translational 
modifications and can transactivate cell cycle-arresting 
and/or lethal genes like CDKN1A (better known as 
p21
CIP1) and/or genes that code for pro-apoptotic 
members of the BCL2 protein family (e.g.,  BAX, 
BBC3), respectively [1]. TP53 has also been shown to 
exert a number of extranuclear activities [2], including 
the induction of mitochondrial membrane 
permeabilization [3], the inhibition of autophagy [4] and 
the degradation of double-stranded RNA [5]. 
 
Recently, Demidenko and colleagues demonstrated that 
TP53 can convert CDKN1A-induced irreversible 
senescence into reversible quiescence through a 
mechanism that involves the central regulator of auto-
phagy mechanistic target of rapamycin (MTOR) [6]. 
Similar to rapamycin (which is well known for its anti-
aging effects) [7],  the accumulation of post-translational- 
 
 



























ly unmodified, transactivation-proficient (but not 
transactivation-deficient) TP53 resulted in MTOR 
inhibition and senescence suppression [6]. These results 
suggest that TP53 can exert cell cycle-arresting and 
senescence-suppressing functions that can be 
uncoupled, at least in selected experimental settings. 
 
Intrigued by these observations, Leontieva et al. have 
studied the response of immortalized WI-38 human 
lung fibroblasts to nutlin-3a (an inhibitor of the 
interaction between TP53 and its major negative 
regulator HDM2) and doxorubicin (a DNA damaging 
agent) [8]. In line with previous results [9], low 
concentrations of doxorubicin induced a prolonged cell 
cycle arrest and were highly efficient in driving WI-38 
cells into senescence, which by definition is 
irreversible. On the contrary, both high doses of 
doxorubicin and nutlin-3a promoted quiescence, a 
reversible cell cycle arrest that can be overcome upon 
the removal of the triggering stimulus.  
 
At the biochemical level, low doses of doxorubicin 
induced a modest accumulation of TP53 and CDKN1A 
transactivation, but did not inhibit the signaling cascade 
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driven into senescence [8]. On the other hand, both high 
doxorubicin concentrations and nutlin-3a provoked 
TP53 superinduction while inhibiting MTOR-mediated 
phosphorylation, a condition that resulted in reversible 
quiescence in spite of normal CDKN1A transactivation 
[8]. Notably, the co-administration of high doxorubicin 
and nutlin-3a led to TP53 hyperaccumulation, complete 
suppression of MTOR activity, poor transactivation of 
CDKN1A and cell death. These results indicate that the 
levels of TP53 and the activation status of the MTOR 
pathway are critical to determine whether, in non-
apoptotic settings, CDKN1A will orchestrate an 
irreversible or a reversible cell cycle arrest [8].  
 
Both TP53 and MTOR are known for their autophagy-
modulatory functions. While nuclear TP53 stimulates 
autophagy by transactivating several pro-autophagic 
genes, both cytoplasmic TP53 and MTOR tonically 
inhibit the autophagic flow [4]. Nutlin-3a-mediated 
senescence suppression (which proceeds through TP53 
superinduction and MTOR inhibition) requires the 
transcriptional functions of TP53, implying that at least 
one, thus far elusive, TP53 target protein is responsible 
for TP53 senescence-suppressing functions [6]. One 
such TP53-responsive protein is sestrin 2, which can 



























12]. However, the exact nature of the relevant p53 
target(s) that regulate the switch between senescence 
and quiescence remains elusive. 
 
Based on the fascinating results obtained by Leontieva 
et al. [8], it can be speculated that nuclear TP53 might 
simultaneously transactivate the cell cycle-arresting 
factor CDKN1A and one or more hitherto unidentified 
anti-senescence (and perhaps pro-autophagic?) 
protein(s) that would operate similar to rapamycin, 
through the inhibition of MTOR. How would then the 
senescence-inducing activity of TP53 prevail over 
TP53-mediated senescence suppression (and vice 
versa)? As a possibility, the promoter of CDKN1A 
might display a high affinity for TP53, while the 
promoter of the TP53 target that suppresses MTOR 
activity might require high TP53 concentrations for 
efficient transactivation. This hypothesis takes into 
consideration the fact that CDKN1A is induced at similar 
levels by both low and high doses of doxorubicin, as well 
as by low and high concentrations of nutlin-3a [8]. In this 
scenario, the accumulation of TP53 beyond a low 
threshold would activate CDKN1A-mediated senescence 
(Figure 1A), whereas high levels of TP53 would be 
required for the ignition of a senescence-suppressing 
program that (once started) would always prevail over the 




































MTOR  activity  is  suppressed  and  CDKN1A‐mediated  cell  cycle  arrest  is  reversible  (quiescence).  By
pharmacologically inhibiting MTOR, rapamycin also exerts senescence‐suppressing functions. 
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confirm or invalidate this hypothesis. Beyond these 
unresolved details, the work by Leontieva et al. added 
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